StreetAlpha.app
Home › Stocks › IVVD

Invivyd, Inc. (IVVD)

Healthcare
Members
LATEST PRICE

Invivyd develops antibody therapies to prevent and treat serious viral infections, starting with COVID-19. IVVD reports earnings on Thu, Nov 5, 2026.

Prices, price targets and earnings estimates for IVVD are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is IVVD in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 5
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated IVVD in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for IVVDThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
BTIGReiterated
Sep 14Buy
Cantor FitzgeraldReiterated
Aug 27Buy
HC Wainwright & Co.Reiterated
Jun 15Buy
DateFirmActionRatingPrice target
Sep 14BTIGReiteratedBuy
Aug 27Cantor FitzgeraldReiteratedBuy
Jun 15HC Wainwright & Co.ReiteratedBuy
Loading…

Seasonality

How IVVD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IVVD in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IVVD is in one of them and how their past IVVD trades turned out.

See how it works→ View all auto pilots→
IVVD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IVVD in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Invivyd

Invivyd is a biopharmaceutical company based in New Haven, Connecticut, that develops antibody therapies for serious viral infectious diseases. Its first authorized product, PEMGARDA, is an antibody used to help prevent COVID-19 in people who are immunocompromised and unlikely to respond well to vaccination. The company is also developing next generation COVID-19 antibodies and early candidates for diseases such as RSV and measles. Its customers are mainly patients and the healthcare providers who treat them.

Headquarters
New Haven, CT
Summary based on the company’s 2026 annual report (10-K) ↗